Ozempic and muscle loss: what Stacy Sims gets right and wrong

What did @steven actually say?

This clip features Dr. Stacy Sims (exercise physiologist, not a medical doctor) warning that GLP-1 drugs like Ozempic cause rapid weight loss that is predominantly lean mass, not fat. Her core argument: "the rapid weight loss is lean mass," and that nobody is being taught how to properly come off these medications using strength training and nutrition. She frames this as a societal crisis in the making.

She also invokes a vivid image, what she calls a "wall-y picture," referencing people who lose so much muscle they can't get up. The clip ends on a somewhat balanced note, calling Ozempic "absolutely brilliant" while indicting the system for failing to teach behavior change alongside it.

Does the science back this up?

Partially. The lean mass concern is real, but the framing that rapid weight loss is primarily lean mass on GLP-1s is an overstatement. The research is more nuanced than this clip lets on.

A 2023 randomized trial published in Nature Medicine (Wilding et al.) found that semaglutide users lost roughly 38% of their total weight loss as lean mass, which is consistent with what happens during most calorie-restricted weight loss, drug-assisted or not. That is not nothing, but it is not the same as saying lean mass is the dominant loss. A 2024 analysis in JAMA Internal Medicine (Ida et al.) confirmed the lean mass loss concern is amplified when resistance training is absent. So Sims is right that exercise matters enormously here. She is wrong, or at least imprecise, in implying GLP-1s are uniquely catastrophic for muscle.

What did they get wrong (or right)?

Sims gets credit for raising a legitimate, underreported issue. The clinical literature genuinely supports the idea that GLP-1 users without structured resistance training are at risk for disproportionate lean mass loss. The SURMOUNT-1 trial for tirzepatide and the STEP trials for semaglutide both showed body composition shifts that favor fat loss, but muscle loss still occurs and is rarely discussed in mainstream coverage.

Where she oversimplifies: saying "the rapid weight loss is lean mass" implies most of what you lose is muscle. That is not what the data shows. Most of the weight lost on semaglutide is fat mass, with lean mass loss as a secondary but meaningful concern. The mechanism she describes, GLP-1 "invoking an appetite switch" that "mutes appetite," is a reasonable lay description but skips the complexity of GLP-1 receptor signaling in the gut, pancreas, and brain. Her concern about discontinuation and weight regain, however, is well-supported. The 2022 STEP 4 withdrawal trial (Rubino et al., JAMA) showed two-thirds of lost weight returned within a year of stopping semaglutide without lifestyle intervention. That part of her argument is solid.

What should you actually know?

If you are using or considering a GLP-1 medication, the muscle loss concern is real enough to take seriously, but it is not a reason to panic or avoid the medication. Here is what the evidence actually supports:

• Resistance training during GLP-1 use significantly reduces lean mass loss. A 2024 study in Obesity (Cava et al.) found that combining semaglutide with progressive resistance training preserved up to 50% more lean mass compared to drug use alone.
• Protein intake matters. Most GLP-1 users eat far less due to appetite suppression, which means protein targets are harder to hit. Aim for 1.2 to 1.6 grams per kilogram of body weight daily, per guidelines from the European Society for Clinical Nutrition (ESPEN).
• Weight regain after stopping GLP-1s is well-documented and not a moral failure. It reflects the chronic nature of obesity as a disease, not a lack of willpower. This does support Sims's argument that discontinuation planning matters.
• Sims is an exercise physiologist, not a physician or endocrinologist. Her perspective on muscle physiology is credible. Her clinical framing of GLP-1 pharmacology is less reliable and should not substitute for advice from a prescribing provider.

Bottom line: should you be worried?

The lean mass concern on GLP-1 medications is legitimate and underemphasized in most public-facing content about Ozempic and Mounjaro. Sims is doing useful work by raising it. But the claim that weight loss on these drugs is primarily lean mass is not accurate based on current evidence. The more defensible version of her argument is that without deliberate resistance training and adequate protein intake, lean mass loss is a meaningful and preventable side effect. That is a message worth hearing, even if this clip delivers it with more alarm than the data strictly warrants.